logo
Select company
Select metric
$ -7.26MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
27
Sector
65
Industry
82
History
65
$ 2.12Close
$ 1.86 - $ 7.1 52-Week Range
Ticker Information

Ticker

INM

Company Name

INMED PHARMACEUTICALS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

INMED PHARMACEUTICALS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

INM - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 534.72K$ -7.79M$ -7.26M
3/31/2025$ 555.5K$ -7.95M$ -7.4M
12/31/2024$ 576.61K$ -7.55M$ -6.98M
9/30/2024$ 600.13K$ -6.81M$ -6.21M
6/30/2024$ 604.52K$ -7.67M$ -7.06M
3/31/2024$ 603.63K$ -6.07M$ -5.47M
12/31/2023$ 602.11K$ -6.35M$ -5.75M
9/30/2023$ 596.85K$ -6.97M$ -6.37M
6/30/2023$ 596K$ -7.93M$ -7.34M
3/31/2023$ 599.09K$ -15.47M$ -14.87M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • INMED PHARMACEUTICALS INC's latest trailing twelve months (TTM) EBITDA stands at $ -9.61M.
  • Over the past 5 years, INMED PHARMACEUTICALS INC's average EBITDA has been $ -10.3M.
  • The median EBITDA for INMED PHARMACEUTICALS INC during this period was $ -7.4M
  • INMED PHARMACEUTICALS INC reached its highest EBITDA over the past 5 years at $ -5.47M.
  • The lowest EBITDA recorded by INMED PHARMACEUTICALS INC in the same timeframe $ -18.53M

INMED PHARMACEUTICALS INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
NBY : NOVABAY PHARMACEUTICALS INC $ 3.61MXBIO : XENETIC BIOSCIENCES INC $ -3.08MSPRB : SPRUCE BIOSCIENCES INC $ -45.81MCPHI : CHINA PHARMA HOLDINGS INC $ -1.74MONCO : ONCONETIX INC $ -43.75MSXTP : 60 DEGREES PHARMACEUTICALS INC $ -7.74MBNBX : APPLIED DNA SCIENCES INC $ -12.85MADTX : ADITXT INC $ -29.78MCDT : CONDUIT PHARMACEUTICALS INC $ -16.52MGTBP : GT BIOPHARMA INC $ -9.39M

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA
EBITDA for INMED PHARMACEUTICALS INC is calculated as follows: EBIT [ $ -9.84M ] + DepAmor [ $ 228.69K ]
(=) EBITDA [ $ -9.61M ]

INM - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -18.53M

Minimum

Sep 30, 2022

$ -5.47M

Maximum

Mar 31, 2024

$ -10.3M

Average

$ -7.4M

Median

EBITDA Benchmark Analysis

The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.9M with a standard deviation of $ 167.01M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.24K
min$ -493.3M
max$ 590.6M
average$ 58.9M
median$ 8.92M
std$ 167.01M